Trials / Completed
CompletedNCT03955913
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
Biomarker Study to Identify Subjects With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,679 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Archival Tumor Tissue Sample | Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue. |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2022-09-19
- Completion
- 2022-09-19
- First posted
- 2019-05-20
- Last updated
- 2023-02-24
Locations
199 sites across 14 countries: United States, Argentina, Belgium, Brazil, France, Germany, Israel, Italy, Japan, Russia, Spain, Turkey (Türkiye), Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT03955913. Inclusion in this directory is not an endorsement.